HK1249446A1 - 用於治療乳糜瀉的組合物和方法 - Google Patents

用於治療乳糜瀉的組合物和方法

Info

Publication number
HK1249446A1
HK1249446A1 HK18109154.3A HK18109154A HK1249446A1 HK 1249446 A1 HK1249446 A1 HK 1249446A1 HK 18109154 A HK18109154 A HK 18109154A HK 1249446 A1 HK1249446 A1 HK 1249446A1
Authority
HK
Hong Kong
Prior art keywords
compositions
treatment
methods
celiac disease
celiac
Prior art date
Application number
HK18109154.3A
Other languages
English (en)
Inventor
Robert Paul Anderson
Jessica Anne Stewart
James Anthony Dromey
Jason Allan Tye-Din
Original Assignee
Immusant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusant Inc filed Critical Immusant Inc
Publication of HK1249446A1 publication Critical patent/HK1249446A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
HK18109154.3A 2008-11-30 2018-07-16 用於治療乳糜瀉的組合物和方法 HK1249446A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11864308P 2008-11-30 2008-11-30

Publications (1)

Publication Number Publication Date
HK1249446A1 true HK1249446A1 (zh) 2018-11-02

Family

ID=42225141

Family Applications (3)

Application Number Title Priority Date Filing Date
HK12103049.1A HK1162918A1 (zh) 2008-11-30 2012-03-28 用於治療腹腔病的組合物和方法
HK16108040.5A HK1219898A1 (zh) 2008-11-30 2016-07-11 用於治療乳糜瀉的組合物和方法
HK18109154.3A HK1249446A1 (zh) 2008-11-30 2018-07-16 用於治療乳糜瀉的組合物和方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK12103049.1A HK1162918A1 (zh) 2008-11-30 2012-03-28 用於治療腹腔病的組合物和方法
HK16108040.5A HK1219898A1 (zh) 2008-11-30 2016-07-11 用於治療乳糜瀉的組合物和方法

Country Status (16)

Country Link
US (5) US8835603B2 (zh)
EP (3) EP2367561B1 (zh)
JP (2) JP5851243B2 (zh)
CN (2) CN105079781B (zh)
AU (1) AU2009321481B2 (zh)
BR (1) BRPI0922122A2 (zh)
CA (2) CA2744787C (zh)
DK (2) DK2367561T3 (zh)
ES (2) ES2549481T3 (zh)
HK (3) HK1162918A1 (zh)
HR (1) HRP20150873T1 (zh)
HU (1) HUE027237T2 (zh)
MX (1) MX346450B (zh)
NZ (1) NZ593474A (zh)
PT (1) PT2367561E (zh)
WO (1) WO2010060155A1 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP2486935B1 (en) 2004-04-28 2021-04-07 BTG International Limited Epitopes related to Coeliac Disease
BRPI0922122A2 (pt) 2008-11-30 2017-08-01 Immusant Inc composições e métodos para tratamento de doença celíaca.
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN107831318B (zh) * 2011-01-20 2021-06-18 西瑞斯实验室有限公司 检测谷蛋白敏感性和其区分于乳糜泻的方法和装置
ITRM20110487A1 (it) * 2011-09-19 2013-03-20 Consiglio Per La Ricerca E La Speri Mentazione In Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca.
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
WO2013119845A1 (en) 2012-02-07 2013-08-15 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
EP3607973A1 (en) 2012-06-21 2020-02-12 Northwestern University Peptide conjugated particles
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
IL303425A (en) 2013-03-13 2023-08-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
CA2906044A1 (en) * 2013-03-14 2014-09-25 Immusant, Inc. Placebo-controlled gluten challenge method
EP2994480A4 (en) * 2013-05-08 2017-05-17 JM Biologicals Compositions and methods for the production of gluten free food products
EP3033102B2 (en) 2013-08-13 2023-12-20 Northwestern University Peptide conjugated particles
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
AU2013400677A1 (en) * 2013-09-20 2016-05-12 Immusant, Inc. Compositions and methods related to oat sensitivity
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
US20170042991A1 (en) * 2014-04-24 2017-02-16 Immusant, Inc. Compositions comprising gluten peptides and uses thereof
NZ730519A (en) * 2014-09-10 2018-10-26 Vibrant Holdings Llc Peptide microarrays and novel biomarkers for celiac disease
EP3201354A1 (en) 2014-09-29 2017-08-09 Immusant Inc. Use of hla genetic status to assess or select treatment of celiac disease
CA2968422A1 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
KR101736744B1 (ko) 2014-12-03 2017-05-17 주식회사 한국유전자정보연구원 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017058074A1 (en) * 2015-08-30 2017-04-06 Diamyd Medical Ab Combination therapy using gliadin and gamma aminobutyric acid
US11510996B2 (en) 2015-12-23 2022-11-29 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
US11484506B2 (en) 2016-02-18 2022-11-01 Cour Pharmaceuticals Development Company, Inc. Process for the preparation of tolerizing immune-modulating particles
US11820833B2 (en) * 2016-06-05 2023-11-21 Tel Hashomer Medical Research Infrastructure And Services Ltd. Peptides that inhibit binding of EPCR to its ligand to treat inflammation
AU2017290080A1 (en) 2016-06-28 2019-01-24 Immusant, Inc. Escalating dosage schedules for treating celiac disease
CA3049624A1 (en) * 2017-01-12 2018-07-19 Probi Ab Probiotic compositions and uses thereof
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
KR20200064085A (ko) 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EP3703728A4 (en) * 2017-10-30 2022-01-05 Immusant Inc. DOSING SCHEMES FOR COELIAKIA
JP6568193B2 (ja) 2017-12-19 2019-08-28 ホーユー株式会社 エピトープ
EP4215186A1 (en) 2018-02-08 2023-07-26 Cour Pharmaceuticals Development Company Inc. Treatment of celiac disease with tolerizing particles
WO2020090979A1 (ja) * 2018-10-31 2020-05-07 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
WO2020181272A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
JP7374687B2 (ja) * 2019-09-26 2023-11-07 三和酒類株式会社 ペンタペプチド化合物
WO2021102182A1 (en) * 2019-11-19 2021-05-27 Spark Therapeutics, Inc. Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disorders
JP2024518277A (ja) 2021-04-16 2024-05-01 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 免疫寛容の維持を追跡する方法
EP4337667A1 (en) 2022-07-21 2024-03-20 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740371A (en) 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
DE3779909T2 (de) 1986-03-06 1993-01-07 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
FR2615622B1 (fr) 1987-05-19 1994-05-06 Ire Medgenix Sa Dosage plasmatique de monokines
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5998366A (en) 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JPH10511541A (ja) 1994-08-26 1998-11-10 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｔ細胞応答を調節するための方法および組成物
AU7726094A (en) 1994-09-02 1996-03-27 Immulogic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
EP1241476A1 (en) 2001-03-12 2002-09-18 Mabtech AB Diagnosis of metal allergy through cytokine release by T-cells in vitro
WO2002080963A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
WO2002083722A2 (en) 2001-04-12 2002-10-24 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
CA2469078A1 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
US7303871B2 (en) 2002-02-14 2007-12-04 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7776545B2 (en) 2002-11-20 2010-08-17 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
WO2003096979A2 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
AU2003277989B2 (en) 2002-11-08 2010-04-22 QIAGEN Australia Holding Pty. Ltd. Diagnostic assay for measuring a cell mediated immune response
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
EP2486935B1 (en) * 2004-04-28 2021-04-07 BTG International Limited Epitopes related to Coeliac Disease
GB0409775D0 (en) 2004-04-30 2004-06-09 Mabtech Ab Assay
CA2585462A1 (en) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1937300A4 (en) 2005-08-17 2009-08-12 Multicell Immunotherapeutics I METHOD AND COMPOSITIONS FOR CREATING AND CONTROLLING THE EFFECTOR PROFILE OF T-CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUB-GROUPS OF ANTIGEN-PRESENTING CELLS
WO2007047303A2 (en) 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン，インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
CA2675297C (en) * 2007-01-25 2019-05-07 Actogenix Nv Treatment of immune disease by mucosal delivery of antigens
ITFE20070003A1 (it) 2007-02-01 2007-05-03 Girolamo Calo' Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa
EP2132569B1 (en) 2007-03-16 2015-10-28 Cellestis Limited A cell-mediated immune response assay and kits therefor
AU2009239558B2 (en) 2008-04-21 2013-05-02 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
WO2009139887A2 (en) 2008-05-16 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue
AU2009273749B2 (en) 2008-07-25 2016-04-21 QIAGEN Australia Holding Pty. Ltd. A diagnostic method
BRPI0922122A2 (pt) 2008-11-30 2017-08-01 Immusant Inc composições e métodos para tratamento de doença celíaca.
WO2011000773A1 (en) 2009-07-02 2011-01-06 Dsm Ip Assets B.V. Testing efficacy for celiac disease
ES2735438T3 (es) 2009-12-23 2019-12-18 Cellestis Ltd Un ensayo para medir la capacidad de respuesta inmune mediada por células
WO2011146968A1 (en) 2010-05-28 2011-12-01 Cellestis Limited A diagnostic assay
US20110311536A1 (en) 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
LT2726883T (lt) 2011-06-29 2018-06-11 Cellestis Limited Padidinto jautrumo ląstelių imuninio atsako įvertinimo būdas
WO2013016427A1 (en) 2011-07-25 2013-01-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
WO2013036303A2 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines
ES2402286B1 (es) 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
AU2012348122B2 (en) 2011-12-05 2017-09-14 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
CA2906044A1 (en) 2013-03-14 2014-09-25 Immusant, Inc. Placebo-controlled gluten challenge method
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
AU2013400677A1 (en) 2013-09-20 2016-05-12 Immusant, Inc. Compositions and methods related to oat sensitivity
US20170042991A1 (en) 2014-04-24 2017-02-16 Immusant, Inc. Compositions comprising gluten peptides and uses thereof

Also Published As

Publication number Publication date
ES2549481T3 (es) 2015-10-28
MX2011005632A (es) 2011-11-29
HK1219898A1 (zh) 2017-04-21
US20150050303A1 (en) 2015-02-19
US9464120B2 (en) 2016-10-11
CA2744787C (en) 2019-06-11
HUE027237T2 (en) 2016-10-28
CA3042826A1 (en) 2010-06-03
AU2009321481A1 (en) 2011-07-07
EP2977053A1 (en) 2016-01-27
US20190048047A1 (en) 2019-02-14
DK2367561T3 (en) 2015-08-24
JP6027215B2 (ja) 2016-11-16
CN105079781A (zh) 2015-11-25
EP3269379A1 (en) 2018-01-17
CA2744787A1 (en) 2010-06-03
DK2977053T3 (en) 2017-10-09
CN102438643B (zh) 2015-07-01
CN102438643A (zh) 2012-05-02
EP2367561A4 (en) 2012-06-06
CN105079781B (zh) 2018-07-20
US20110293644A1 (en) 2011-12-01
PT2367561E (pt) 2015-10-23
US20170158743A1 (en) 2017-06-08
MX346450B (es) 2017-03-17
AU2009321481B2 (en) 2014-08-21
US20210115096A1 (en) 2021-04-22
WO2010060155A1 (en) 2010-06-03
EP2367561B1 (en) 2015-05-20
HRP20150873T1 (hr) 2015-11-06
JP5851243B2 (ja) 2016-02-03
HK1162918A1 (zh) 2012-09-07
BRPI0922122A2 (pt) 2017-08-01
US8835603B2 (en) 2014-09-16
EP2367561A1 (en) 2011-09-28
ES2642096T3 (es) 2017-11-15
JP2012510431A (ja) 2012-05-10
EP2977053B1 (en) 2017-07-05
JP2016128402A (ja) 2016-07-14
NZ593474A (en) 2013-04-26

Similar Documents

Publication Publication Date Title
HK1249446A1 (zh) 用於治療乳糜瀉的組合物和方法
IL258794B (en) Methods and preparations for the diagnosis and treatment of cancer
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL208354A0 (en) Methods of treatment
ZA201105472B (en) Methods and compositions for diagnosis and treatment of cancer
HK1159498A1 (zh) 用於治療癌症的方法和組合物
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
ZA201006988B (en) Method and compositions for treatment of cancer
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
ZA201008201B (en) Novel compositions and methods for treating hyperproliferative diseases
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2405747A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
HK1157228A1 (en) Compositions and methods of treating amyloid disease
EP2411031A4 (en) Methods and compositions for the treatment of cancer
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia